ClinicalTrials.gg
CompletedNCT01306162Updated Jun 6, 2014Results posted

Drug Interaction Study With Dabigatran Etexilate and Dronedarone in Healthy Subjects

A Phase 1 interventional study of Dabigatran etexilate plus dronedarone and Dabigatran etexilate in Healthy, sponsored by Boehringer Ingelheim. Completed at 1 site in Germany. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-06-06.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Study summary

The objective of the study is to assess the relative bioavailability of a single dose of dabigatran after concomitant multiple oral administration of dronedarone with the aim to investigate whether and to what extent the P-gp inhibitor dronedarone affects pharmacokinetic parameters of dabigatran when administered to healthy subjects

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.

Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy male and female subjects

Exclusion criteria

Exclusion criteria:

  1. Any relevant deviation from healthy conditions
05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    A: Dabigatran alone (Reference)

    Capsule, oral administration with 240 mL water

    Drug: Dabigatran etexilate

  • Experimental
    B: Dabigatran plus Dronedarone (Test)

    Capsule and Tablets, oral administration with 240 mL water

    Drug: Dabigatran etexilate plus dronedarone

  • Experimental
    C: Dabigatran plus Dronedarone (Test)

    Capsule and Tablets, oral administration with 240 mL water

    Drug: Dabigatran etexilate plus dronedarone

  • Experimental
    D: Dabigatran plus Dronedarone (Test)

    Capsule and Tablets, oral administration with 240 mL water

    Drug: Dabigatran etexilate plus dronedarone

  • Experimental
    E: Dabigatran plus Dronedarone (Test)

    Capsule and Tablets, oral administration with 240 mL water

    Drug: Dabigatran etexilate plus dronedarone

Interventions

  • DrugDabigatran etexilate plus dronedarone

    Drug pages: Dabigatran · Dronedarone

    dabigatran etexilate 150 mg plus dronedarone 400 mg as single dose

  • 150 mg as single dose

  • DrugDabigatran etexilate plus dronedarone

    Drug pages: Dabigatran · Dronedarone

    dabigatran etexilate 150 mg plus dronedarone 400 mg as single dose (staggered administration)

  • DrugDabigatran etexilate plus dronedarone

    Drug pages: Dabigatran · Dronedarone

    dabigatran etexilate 150 mg single dose plus dronedarone 400 mg bid

  • DrugDabigatran etexilate plus dronedarone

    Drug pages: Dabigatran · Dronedarone

    dabigatran etexilate 150 mg single dose plus dronedarone 400 mg bid (staggered administration)

06

What researchers measure

Primary outcomes

  1. Total Dabigatran: Area Under the Curve 0 to Infinity (AUC0-∞)

    Area under the concentration-time curve of total dabigatran in plasma over the time interval from 0 extrapolated to infinity.

    Time frame: 1 h before drug administration and 0:30, 1:00, 1:30, 2:00, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 24:00, 36:00, 48:00 h after drug administration

  2. Total Dabigatran: Maximum Measured Concentration (Cmax)

    Maximum measured concentration of total dabigatran in plasma, per period.

    Time frame: 1 h before drug administration and 0:30, 1:00, 1:30, 2:00, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 24:00, 36:00, 48:00 h after drug administration

Secondary outcomes

  1. Free Dabigatran: Area Under the Curve 0 to Infinity (AUC0-∞)

    Area under the concentration-time curve of free dabigatran in plasma over the time interval from 0 extrapolated to infinity.

    Time frame: 1 h before drug administration and 0:30, 1:00, 1:30, 2:00, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 24:00, 36:00, 48:00 h after drug administration

  2. Free Dabigatran: Maximum Measured Concentration (Cmax)

    Maximum measured concentration of free dabigatran in plasma, per period.

    Time frame: 1 h before drug administration and 0:30, 1:00, 1:30, 2:00, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 24:00, 36:00, 48:00 h after drug administration

07

Results

Posted Aug 14, 2012

Participant flow

Period 1
Participant flow — Period 1
MilestoneTrtA -- TrtB -- TrtD -- TrtETrtA -- TrtC -- TrtE -- TrtDTrtB -- TrtD -- TrtE -- TrtATrtC -- TrtE -- TrtD -- TrtA
Started9999
Completed9998
Not completed0001
Withdrew: Adverse event0001
Washout 1
Participant flow — Washout 1
MilestoneTrtA -- TrtB -- TrtD -- TrtETrtA -- TrtC -- TrtE -- TrtDTrtB -- TrtD -- TrtE -- TrtATrtC -- TrtE -- TrtD -- TrtA
Started9998
Completed9898
Not completed0100
Withdrew: Non-compliance to protocol0100
Period 2
Participant flow — Period 2
MilestoneTrtA -- TrtB -- TrtD -- TrtETrtA -- TrtC -- TrtE -- TrtDTrtB -- TrtD -- TrtE -- TrtATrtC -- TrtE -- TrtD -- TrtA
Started9898
Completed9898
Not completed0000
Period 3
Participant flow — Period 3
MilestoneTrtA -- TrtB -- TrtD -- TrtETrtA -- TrtC -- TrtE -- TrtDTrtB -- TrtD -- TrtE -- TrtATrtC -- TrtE -- TrtD -- TrtA
Started9898
Completed9898
Not completed0000
Washout 2
Participant flow — Washout 2
MilestoneTrtA -- TrtB -- TrtD -- TrtETrtA -- TrtC -- TrtE -- TrtDTrtB -- TrtD -- TrtE -- TrtATrtC -- TrtE -- TrtD -- TrtA
Started9898
Completed9898
Not completed0000
Period 4
Participant flow — Period 4
MilestoneTrtA -- TrtB -- TrtD -- TrtETrtA -- TrtC -- TrtE -- TrtDTrtB -- TrtD -- TrtE -- TrtATrtC -- TrtE -- TrtD -- TrtA
Started9898
Completed9898
Not completed0000

Outcome measures

PrimaryTotal Dabigatran: Area Under the Curve 0 to Infinity (AUC0-∞)

Area under the concentration-time curve of total dabigatran in plasma over the time interval from 0 extrapolated to infinity.

Time frame:
1 h before drug administration and 0:30, 1:00, 1:30, 2:00, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 24:00, 36:00, 48:00 h after drug administration
Reported as:
Geometric mean · ng*hr/mL
Total Dabigatran: Area Under the Curve 0 to Infinity (AUC0-∞)
ng*hr/mL150mg DE (TrtA)150mg DE + 400mg DR (TrtB)150mg DE + 400mg DR 2h Later (TrtC)150mg DE + 400mg DR Bid Same Time (TrtD)150mg DE + 400mg DR Bid 2h Later (TrtE)
Total Dabigatran: Area Under the Curve 0 to Infinity (AUC0-∞)1160 ± 40.32520 ± 27.11440 ± 40.32570 ± 28.11510 ± 32.9
Statistical analysis
  • 150mg DE (TrtA) vs 150mg DE + 400mg DR (TrtB) · ANOVA · p = 1.0000 (p-value for geometric mean ratio being outside interval 80% to 125%) · Geometric mean ratio trtb: trta (%): 214 · 90% CI 191 to 240The standard deviation is actually the Geometric coefficient of variation.
  • 150mg DE (TrtA) vs 150mg DE + 400mg DR 2h Later (TrtC) · ANOVA · p = 0.6697 (p-value for geometric mean ratio being outside interval 80% to 125%) · Geometric mean ratio trtc: trta (%): 130 · 90% CI 112 to 151The standard deviation is actually the Geometric coefficient of variation
  • 150mg DE (TrtA) vs 150mg DE + 400mg DR Bid Same Time (TrtD) · ANOVA · p = 0.9992 (p-value for geometric mean ratio being outside interval 80% to 125%) · Geometric mean ratio trtd: trta (%): 236 · 90% CI 173 to 321The standard deviation is actually the Geometric coefficient of variation
  • 150mg DE (TrtA) vs 150mg DE + 400mg DR Bid 2h Later (TrtE) · ANOVA · p = 0.9171 (p-value for geometric mean ratio being outside interval 80% to 125%) · Geometric mean ratio trte: trta (%): 162 · 90% CI 119 to 221The standard deviation is actually the Geometric coefficient of variation
PrimaryTotal Dabigatran: Maximum Measured Concentration (Cmax)

Maximum measured concentration of total dabigatran in plasma, per period.

Time frame:
1 h before drug administration and 0:30, 1:00, 1:30, 2:00, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 24:00, 36:00, 48:00 h after drug administration
Reported as:
Geometric mean · ng/mL
Total Dabigatran: Maximum Measured Concentration (Cmax)
ng/mL150mg DE (TrtA)150mg DE + 400mg DR (TrtB)150mg DE + 400mg DR 2h Later (TrtC)150mg DE + 400mg DR Bid Same Time (TrtD)150mg DE + 400mg DR Bid 2h Later (TrtE)
Total Dabigatran: Maximum Measured Concentration (Cmax)149 ± 46.0282 ± 30.1166 ± 37.5288 ± 29.9163 ± 30.9
Statistical analysis
  • 150mg DE (TrtA) vs 150mg DE + 400mg DR (TrtB) · ANOVA · p = 0.9999 (p-value for geometric mean ratio being outside interval 80% to 125%) · Geometric mean ratio trtb: trta (%): 187 · 90% CI 162 to 215The standard deviation is actually the Geometric coefficient of variation
  • 150mg DE (TrtA) vs 150mg DE + 400mg DR 2h Later (TrtC) · ANOVA · p = 0.2207 (p-value for geometric mean ratio being outside interval 80% to 125%) · Geometric mean ratio trtc: trta (%): 115 · 90% CI 95 to 138The standard deviation is actually the Geometric coefficient of variation
  • 150mg DE (TrtA) vs 150mg DE + 400mg DR Bid Same Time (TrtD) · ANOVA · p = 0.9946 (p-value for geometric mean ratio being outside interval 80% to 125%) · Geometric mean ratio trtd: trta (%): 225 · 90% CI 156 to 326The standard deviation is actually the Geometric coefficient of variation
  • 150mg DE (TrtA) vs 150mg DE + 400mg DR Bid 2h Later (TrtE) · ANOVA · p = 0.6221 (p-value for geometric mean ratio being outside interval 80% to 125%) · Geometric mean ratio trte: trta (%): 133 · 90% CI 94 to 190The standard deviation is actually the Geometric coefficient of variation
SecondaryFree Dabigatran: Area Under the Curve 0 to Infinity (AUC0-∞)

Area under the concentration-time curve of free dabigatran in plasma over the time interval from 0 extrapolated to infinity.

Time frame:
1 h before drug administration and 0:30, 1:00, 1:30, 2:00, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 24:00, 36:00, 48:00 h after drug administration
Reported as:
Geometric mean · ng*hr/mL
Free Dabigatran: Area Under the Curve 0 to Infinity (AUC0-∞)
ng*hr/mL150mg DE (TrtA)150mg DE + 400mg DR (TrtB)150mg DE + 400mg DR 2h Later (TrtC)150mg DE + 400mg DR Bid Same Time (TrtD)150mg DE + 400mg DR Bid 2h Later (TrtE)
Free Dabigatran: Area Under the Curve 0 to Infinity (AUC0-∞)919 ± 47.52110 ± 27.41110 ± 47.22100 ± 30.51260 ± 36.0
Statistical analysis
  • 150mg DE (TrtA) vs 150mg DE + 400mg DR (TrtB) · ANOVA · p = 1.0000 (p-value for geometric mean ratio being outside interval 80% to 125%) · Geometric mean ratio trtb: trta (%): 214 · 90% CI 190 to 241The standard deviation is actually the Geometric coefficient of variation
  • 150mg DE (TrtA) vs 150mg DE + 400mg DR 2h Later (TrtC) · ANOVA · p = 0.7223 (p-value for geometric mean ratio being outside interval 80% to 125%) · Geometric mean ratio trtc: trta (%): 132 · 90% CI 113 to 155The standard deviation is actually the Geometric coefficient of variation
  • 150mg DE (TrtA) vs 150mg DE + 400mg DR Bid Same Time (TrtD) · ANOVA · p = 0.9993 (p-value for geometric mean ratio being outside interval 80% to 125%) · Geometric mean ratio trtd: trta (%): 258 · 90% CI 182 to 365The standard deviation is actually the Geometric coefficient of variation
  • 150mg DE (TrtA) vs 150mg DE + 400mg DR Bid 2h Later (TrtE) · ANOVA · p = 0.8875 (p-value for geometric mean ratio being outside interval 80% to 125%) · Geometric mean ratio trte: trta (%): 159 · 90% CI 114 to 222The standard deviation is actually the Geometric coefficient of variation
SecondaryFree Dabigatran: Maximum Measured Concentration (Cmax)

Maximum measured concentration of free dabigatran in plasma, per period.

Time frame:
1 h before drug administration and 0:30, 1:00, 1:30, 2:00, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 24:00, 36:00, 48:00 h after drug administration
Reported as:
Geometric mean · ng/mL
Free Dabigatran: Maximum Measured Concentration (Cmax)
ng/mL150mg DE (TrtA)150mg DE + 400mg DR (TrtB)150mg DE + 400mg DR 2h Later (TrtC)150mg DE + 400mg DR Bid Same Time (TrtD)150mg DE + 400mg DR Bid 2h Later (TrtE)
Free Dabigatran: Maximum Measured Concentration (Cmax)126 ± 48.0239 ± 27.6133 ± 40.7241 ± 29.5138 ± 34.0
Statistical analysis
  • 150mg DE (TrtA) vs 150mg DE + 400mg DR (TrtB) · ANOVA · p = 0.9998 (p-value for geometric mean ratio being outside interval 80% to 125%) · Geometric mean ratio trtb: trta (%): 180 · 90% CI 156 to 207The standard deviation is actually the Geometric coefficient of variation
  • 150mg DE (TrtA) vs 150mg DE + 400mg DR 2h Later (TrtC) · ANOVA · p = 0.1866 (p-value for geometric mean ratio being outside interval 80% to 125%) · Geometric mean ratio trtc: trta (%): 114 · 90% CI 95 to 136The standard deviation is actually the Geometric coefficient of variation
  • 150mg DE (TrtA) vs 150mg DE + 400mg DR Bid Same Time (TrtD) · ANOVA · p = 0.9958 (p-value for geometric mean ratio being outside interval 80% to 125%) · Geometric mean ratio trtd: trta (%): 234 · 90% CI 160 to 340The standard deviation is actually the Geometric coefficient of variation
  • 150mg DE (TrtA) vs 150mg DE + 400mg DR Bid 2h Later (TrtE) · ANOVA · p = 0.5164 (p-value for geometric mean ratio being outside interval 80% to 125%) · Geometric mean ratio trte: trta (%): 126 · 90% CI 89 to 179The standard deviation is actually the Geometric coefficient of variation

Adverse events

Collected over 14 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
150mg DE (TrtA)—0/35 (0%)3/35 (8.6%)
150mg DE + 400mg DR (TrtB)—0/18 (0%)6/18 (33.3%)
150mg DE + 400mg DR 2h Later (TrtC)—0/17 (0%)5/17 (29.4%)
150mg DE + 400mg DR Bid Same Time (TrtD)—0/34 (0%)5/34 (14.7%)
150mg DE + 400mg DR Bid 2h Later (TrtE)—0/30 (0%)3/30 (10%)
400mg DR + 400mg DR Bid 2h Later (TrtE2)—0/4 (0%)0/4 (0%)
Most frequent other events
Showing 10 of 13
Most frequent other events
Event150mg DE (TrtA)150mg DE + 400mg DR (TrtB)150mg DE + 400mg DR 2h Later (TrtC)150mg DE + 400mg DR Bid Same Time (TrtD)150mg DE + 400mg DR Bid 2h Later (TrtE)400mg DR + 400mg DR Bid 2h Later (TrtE2)
HeadacheNervous system disorders3/354/181/172/342/300/4
Atrioventricular block first degreeCardiac disorders0/350/181/170/340/300/4
PalpitationsCardiac disorders0/350/181/170/340/300/4
CoughRespiratory, thoracic and mediastinal disorders0/350/181/171/340/300/4
DysphoniaRespiratory, thoracic and mediastinal disorders0/350/181/170/340/300/4
DyspnoeaRespiratory, thoracic and mediastinal disorders0/350/181/170/340/300/4
Oropharyngeal painRespiratory, thoracic and mediastinal disorders0/351/181/170/340/300/4
Gastric disorderGastrointestinal disorders0/351/181/170/341/300/4
ArthralgiaMusculoskeletal and connective tissue disorders0/350/181/170/340/300/4
MenorrhagiaReproductive system and breast disorders0/350/181/170/340/300/4

Baseline characteristics

Treated set contains of all subjects who were dispensed study medication and were documented to have taken at least one dose of study drug.

Age, Continuous
Age, Continuous(Years)TrtA -- TrtB -- TrtD -- TrtETrtA -- TrtC -- TrtE -- TrtDTrtB -- TrtD -- TrtE -- TrtATrtC -- TrtE -- TrtD -- TrtATotal
Mean32.2 ± 10.737.8 ± 10.438.1 ± 9.733.3 ± 7.935.4 ± 9.6
Sex: Female, Male
Sex: Female, Male(Participants)TrtA -- TrtB -- TrtD -- TrtETrtA -- TrtC -- TrtE -- TrtDTrtB -- TrtD -- TrtE -- TrtATrtC -- TrtE -- TrtD -- TrtATotal
Female752519
Male247417
08

Study locations

1 site
  • 1160.112.1 Boehringer Ingelheim Investigational Site
    Ulm, Germany
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2011 and a primary completion of May 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2012, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 28, 2011
First posted
Mar 1, 2011
Start
Feb 2011
Primary completionActual
May 2011
Results first posted
Aug 14, 2012
Last update
Jun 6, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 6, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01306162
Responsible party
Sponsor
First posted
Mar 1, 2011
Start date
Feb 2011
Primary completion
May 2011
Results posted
Aug 14, 2012
Last update
Jun 6, 2014

Study contacts

Boehringer Ingelheim
study chair · Boehringer Ingelheim
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Dabigatran · Dronedarone

Start the discussion